

CITI GOOD LABORATORY BEHAVIOR PRACTICE TEST (SAMPLE)

STUDY GUIDE



SAMPLE STUDY GUIDE WITH LIMITED QUESTIONS

VISIT US ONLINE FOR
THE FULL VERSION STUDY GUIDE

<https://citigoodlabbehavior.examzify.com>



Copyright © 2026 by Examzify - A Kaluba Technologies Inc. product.

ALL RIGHTS RESERVED.

No part of this book may be reproduced or transferred in any form or by any means, graphic, electronic, or mechanical, including photocopying, recording, web distribution, taping, or by any information storage retrieval system, without the written permission of the author.

Notice: Examzify makes every reasonable effort to obtain accurate, complete, and timely information about this product from reliable sources.

SAMPLE

Table of Contents

Copyright	1
Table of Contents	2
Introduction	3
How to Use This Guide	4
Questions	5
Answers	8
Explanations	10
Next Steps	15

SAMPLE

Introduction

Preparing for a certification exam can feel overwhelming, but with the right tools, it becomes an opportunity to build confidence, sharpen your skills, and move one step closer to your goals. At Examzify, we believe that effective exam preparation isn't just about memorization, it's about understanding the material, identifying knowledge gaps, and building the test-taking strategies that lead to success.

This guide was designed to help you do exactly that.

Whether you're preparing for a licensing exam, professional certification, or entry-level qualification, this book offers structured practice to reinforce key concepts. You'll find a wide range of multiple-choice questions, each followed by clear explanations to help you understand not just the right answer, but why it's correct.

The content in this guide is based on real-world exam objectives and aligned with the types of questions and topics commonly found on official tests. It's ideal for learners who want to:

- Practice answering questions under realistic conditions,
- Improve accuracy and speed,
- Review explanations to strengthen weak areas, and
- Approach the exam with greater confidence.

We recommend using this book not as a stand-alone study tool, but alongside other resources like flashcards, textbooks, or hands-on training. For best results, we recommend working through each question, reflecting on the explanation provided, and revisiting the topics that challenge you most.

Remember: successful test preparation isn't about getting every question right the first time, it's about learning from your mistakes and improving over time. Stay focused, trust the process, and know that every page you turn brings you closer to success.

Let's begin.

How to Use This Guide

This guide is designed to help you study more effectively and approach your exam with confidence. Whether you're reviewing for the first time or doing a final refresh, here's how to get the most out of your Examzify study guide:

1. Start with a Diagnostic Review

Skim through the questions to get a sense of what you know and what you need to focus on. Your goal is to identify knowledge gaps early.

2. Study in Short, Focused Sessions

Break your study time into manageable blocks (e.g. 30 – 45 minutes). Review a handful of questions, reflect on the explanations.

3. Learn from the Explanations

After answering a question, always read the explanation, even if you got it right. It reinforces key points, corrects misunderstandings, and teaches subtle distinctions between similar answers.

4. Track Your Progress

Use bookmarks or notes (if reading digitally) to mark difficult questions. Revisit these regularly and track improvements over time.

5. Simulate the Real Exam

Once you're comfortable, try taking a full set of questions without pausing. Set a timer and simulate test-day conditions to build confidence and time management skills.

6. Repeat and Review

Don't just study once, repetition builds retention. Re-attempt questions after a few days and revisit explanations to reinforce learning. Pair this guide with other Examzify tools like flashcards, and digital practice tests to strengthen your preparation across formats.

There's no single right way to study, but consistent, thoughtful effort always wins. Use this guide flexibly, adapt the tips above to fit your pace and learning style. You've got this!

Questions

SAMPLE

- 1. What type of data entries first alerted FDA investigators to problems?**
 - A. Inconsistent and/or unexplained entries in data submitted to the FDA
 - B. Missing pages in the dossier
 - C. Outdated test methods
 - D. Unapproved methods
- 2. The environment of an animal housing room refers to which of the following?**
 - A. The temperature and the relative humidity range at any point in time
 - B. Lighting duration
 - C. Noise level
 - D. Ventilation rate
- 3. A GLP memorandum of understanding (MOU) between an OECD-member country and the U.S. would permit:**
 - A. Acceptance of final reports and data conducted in either country under their applicable GLP regulations
 - B. Acceptance of only U.S. GLP data
 - C. Acceptance of only OECD GLP data
 - D. No cross-acceptance of data
- 4. What best describes data integrity in GLP?**
 - A. Data are accurate, complete, and verifiable, allowing review and audit.
 - B. Data may be approximate if the study design is robust.
 - C. Only the final report data need be accurate.
 - D. Data integrity is optional if QA is strong.
- 5. A GLP memorandum of understanding between an OECD-member country and the U.S. would permit acceptance of final reports and data conducted in either country under their applicable GLP regulations. This means acceptance of data:**
 - A. In either country under their GLP regulations
 - B. Only in the U.S. under U.S. GLP regulations
 - C. Only in OECD member countries under OECD GLP regulations
 - D. Not cross-accepted between countries

- 6. In GLP, a study is not considered complete until what occurs?**
- A. The archive is created
 - B. The final report is signed
 - C. The QA audit is completed
 - D. The raw data is transferred to the sponsor
- 7. Which labeling feature is essential for test articles in GLP to prevent mix-ups?**
- A. Only the article name.
 - B. Clear labeling that identifies the article, batch/lot, and storage conditions.
 - C. No labeling is required if the article is identical to others.
 - D. Labeling that matches the supplier's generic label.
- 8. What should data reconciliation across sites demonstrate?**
- A. Comparing data with source data on a regular basis to ensure accuracy
 - B. Disregarding discrepancies
 - C. Archiving data without validation
 - D. Reconciliation is optional
- 9. Who provided the multiple batches of All-Slide3 received from the sponsor?**
- A. The sponsor
 - B. The FDA
 - C. A third-party vendor
 - D. The test facility QA
- 10. Distinguish protocol amendments from deviations and how each is documented.**
- A. Deviations are unplanned departures documented with rationale and impact
 - B. Amendments modify the protocol with approvals; deviations are unplanned departures documented with rationale and impact
 - C. Amendments modify the protocol with approvals and no documentation of deviations
 - D. Neither require documentation

Answers

SAMPLE

1. A
2. A
3. A
4. B
5. A
6. B
7. B
8. A
9. A
10. B

SAMPLE

Explanations

SAMPLE

1. What type of data entries first alerted FDA investigators to problems?

- A. Inconsistent and/or unexplained entries in data submitted to the FDA
- B. Missing pages in the dossier
- C. Outdated test methods
- D. Unapproved methods

The key idea here is data integrity: records must be complete, accurate, and fully explainable so the study's results can be trusted. When investigators review data submitted to the FDA, they look for anything that calls that trust into question. Inconsistent and/or unexplained entries signal that the data aren't being recorded and reported transparently. They create doubt about whether observations were recorded correctly, whether edits were authorized, or whether data were fabricated or inappropriately altered. That kind of flag prompts investigators to dig deeper into the entire data set and the study conduct. Other issues like missing pages, outdated test methods, or unapproved methods are also problematic and can lead to noncompliance, but they don't point to a data integrity problem as directly or as early as inconsistent or unexplained data entries. The consistency and justification of what was recorded is the first line of evidence that something in the data handling may be compromised.

2. The environment of an animal housing room refers to which of the following?

- A. The temperature and the relative humidity range at any point in time
- B. Lighting duration
- C. Noise level
- D. Ventilation rate

In this context, the environment of an animal housing room is defined by the actual physical conditions the animals experience, with temperature and relative humidity being the most fundamental measures of those conditions. These two factors directly influence comfort, metabolism, hydration, and health, and they're routinely monitored to keep animals within a stable, acceptable range. While lighting duration, noise level, and ventilation rate matter for welfare and air quality, they describe additional aspects of the environment rather than defining its core state. Keeping temperature and humidity within appropriate ranges ensures animals remain comfortable and that experimental results are reliable, which is why this option best captures the environment.

3. A GLP memorandum of understanding (MOU) between an OECD-member country and the U.S. would permit:

- A. Acceptance of final reports and data conducted in either country under their applicable GLP regulations
- B. Acceptance of only U.S. GLP data
- C. Acceptance of only OECD GLP data
- D. No cross-acceptance of data

Cross-border recognition of GLP data is what this item is testing. An MOU between an OECD-member country and the U.S. is meant to foster mutual acceptance of GLP-compliant studies, so that final reports and data generated in either country under each nation's GLP regulations can be used in regulatory submissions in the other country. This arrangement helps avoid duplicative testing and speeds up the regulatory process while preserving data quality and traceability—data produced in one country under its GLP rules is acceptable to the other country as long as it meets those GLP requirements. The other options imply restricting acceptance to data from only one side or forbidding cross-acceptance, which is not the intended outcome of such an MOU.

4. What best describes data integrity in GLP?

- A. Data are accurate, complete, and verifiable, allowing review and audit.
- B. Data may be approximate if the study design is robust.**
- C. Only the final report data need be accurate.
- D. Data integrity is optional if QA is strong.

Data integrity in GLP means data are accurate, complete, and verifiable, so they can be reviewed and audited. In practice, this means records are attributable to the person who generated them, legible, contemporaneous with the observation, original or a true copy, and accurate. The systems used to collect and store data should preserve their authenticity over time, with proper change control and traceability so an auditor can confirm what happened and when. The idea that data may be approximate if the study design is robust misses the core point: integrity requires data truly reflect what was observed, not a best-guess version. Robust design does not excuse inaccuracy or incompleteness. Likewise, it's not acceptable to limit the expectation of integrity to final report data; regulators and QA expect raw data and source documents to be complete and trustworthy, because the final conclusions depend on the entire data trail. Finally, data integrity isn't optional because QA is strong—QA supports integrity, but it cannot substitute for proper data capture, retention, and traceability across the study.

5. A GLP memorandum of understanding between an OECD-member country and the U.S. would permit acceptance of final reports and data conducted in either country under their applicable GLP regulations. This means acceptance of data:

- A. In either country under their GLP regulations**
- B. Only in the U.S. under U.S. GLP regulations
- C. Only in OECD member countries under OECD GLP regulations
- D. Not cross-accepted between countries

The key idea here is mutual recognition of GLP data between the United States and an OECD member country. When a GLP memorandum of understanding exists, final reports and data produced in either country under that country's GLP regulations are acceptable in the other country's regulatory system. In practice, this means a study conducted in one jurisdiction can be used to support regulatory decisions in the other, as long as it was performed under the relevant GLP rules and is properly documented. So data from the U.S. can be accepted in the OECD member country and data from that country can be accepted in the U.S., without needing to redo the study under the other country's GLP framework.

6. In GLP, a study is not considered complete until what occurs?

- A. The archive is created
- B. The final report is signed**
- C. The QA audit is completed
- D. The raw data is transferred to the sponsor

In GLP, the official close of a study happens when the final report is signed by the Study Director. That signature signals that the report has been reviewed, approved, and accurately reflects the study's design, conduct, data, and conclusions. The final report is the formal, auditable document that documents what was planned, what was done, what was found, and what it means. Without this signature, the study isn't considered complete because there's no validated record of its outcomes. Other activities like creating the archive, completing the QA audit, or transferring raw data to the sponsor are essential parts of GLP practice to ensure integrity, traceability, and proper data handling, but they do not by themselves mark the completion of the study. Archiving preserves records for future access; QA audits verify compliance and data integrity; transferring data to the sponsor facilitates dissemination. The signed final report ties all of these elements together into a formally completed study.

7. Which labeling feature is essential for test articles in GLP to prevent mix-ups?

- A. Only the article name.
- B. Clear labeling that identifies the article, batch/lot, and storage conditions.**
- C. No labeling is required if the article is identical to others.
- D. Labeling that matches the supplier's generic label.

In GLP, keeping test articles clearly identified is essential to prevent mix-ups and preserve study integrity. The key labeling should convey exactly what the item is, which batch or lot it came from, and how it must be stored. This combination creates a reliable trail that lets you distinguish between similar items, track materials through every step of the study, and verify that each sample is handled under appropriate conditions. If you label only with the article name, you risk confusing items that look alike or come from different production runs, which can lead to mixing samples and invalid results. Omitting batch or lot information makes it impossible to determine which results came from which production batch, hindering traceability and quality control. Relying solely on a supplier's generic label can ignore internal handling requirements, storage instructions, or internal tracking needs that are critical for GLP compliance. By ensuring a clear label includes the article identity, batch/lot, and storage conditions, you create a robust system for accurate identification, proper handling, and traceability throughout the testing process.

8. What should data reconciliation across sites demonstrate?

- A. Comparing data with source data on a regular basis to ensure accuracy**
- B. Disregarding discrepancies
- C. Archiving data without validation
- D. Reconciliation is optional

Data reconciliation across sites is about ensuring data integrity by regularly comparing what's recorded at each site with the original source data to confirm accuracy. This routine cross-checks help detect and fix errors, inconsistencies, or drift between systems, so that all locations reflect the same, correct information. That's why the best choice emphasizes comparing data to source data on a regular basis to verify accuracy—the heart of trustworthy, harmonized data across sites. Disregarding discrepancies would let errors slip through and undermine reliability. Archiving data without validation skips the crucial step of confirming accuracy before keeping records. Saying reconciliation is optional ignores the fundamental need for consistent, verified data in multi-site environments.

9. Who provided the multiple batches of All-Slide3 received from the sponsor?

- A. The sponsor**
- B. The FDA
- C. A third-party vendor
- D. The test facility QA

In GLP studies, the sponsor is the entity responsible for providing the test article and all related materials used in the study. The vendor or manufacturing partners may be involved in producing the batches, but they do so under the sponsor's direction, and the sponsor ultimately supplies the material to the testing facility. The FDA is the regulatory body that oversees GLP compliance, not a supplier of study materials. The test facility QA ensures quality and proper documentation of materials and procedures, but does not supply the test article itself. So receiving multiple batches of All-Slide3 from the sponsor reflects the sponsor's role in provisioning the study materials.

10. Distinguish protocol amendments from deviations and how each is documented.

- A. Deviations are unplanned departures documented with rationale and impact
- B. Amendments modify the protocol with approvals; deviations are unplanned departures documented with rationale and impact**
- C. Amendments modify the protocol with approvals and no documentation of deviations
- D. Neither require documentation

In protocol management, planned changes and unexpected events are handled differently to maintain governance and traceability. An amendment is a planned modification to the protocol that undergoes formal review and receives approvals before it is put into use; the change is documented with updated protocol text, version numbers, and the approval records. A deviation is an unplanned departure from the protocol as it is being carried out; it is documented after the fact with the rationale for the departure and an assessment of its potential impact on participant safety, data integrity, or study outcomes, along with any corrective actions taken. This approach keeps authorized updates clearly recorded and separately tracks unexpected issues so they can be reviewed and addressed. That's why the statement describing amendments as modifying the protocol with approvals and deviations as unplanned departures documented with rationale and impact is the best fit.

Next Steps

Congratulations on reaching the final section of this guide. You've taken a meaningful step toward passing your certification exam and advancing your career.

As you continue preparing, remember that consistent practice, review, and self-reflection are key to success. Make time to revisit difficult topics, simulate exam conditions, and track your progress along the way.

If you need help, have suggestions, or want to share feedback, we'd love to hear from you. Reach out to our team at hello@examzify.com.

Or visit your dedicated course page for more study tools and resources:

<https://citigoodlabbehavior.examzify.com>

We wish you the very best on your exam journey. You've got this!

SAMPLE